CVS Health (CVS) IV elevated as shares near three-year low into Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
CVS Health (CVS) PT Lowered to $76 at Jefferies Following 3Q
November 7, 2017 8:24 AM ESTJefferies lowered its price target on CVS Health (NYSE: CVS) to $76.00 (from $86.00) while maintaining a Hold rating. CVS reported Q3 EPS of $1.50 that beat consensus by $0.02. Similar to the last few quarters, SSS revs were pressured by weakness in front-end sales and the... More
